Rtw Biotech Regulatory News (RTW)

LEI: 549300Q7EXQQH6KF7Z84

26 February 2020

RTW Venture Fund Limited

(the "Company")

ISSUE OF EQUITY

On 25 February 2020, the Company issued 357,565 new ordinary shares of no par value each at a price of US$1.32 per share; these shares rank pari passu with the existing ordinary shares in issue. The issue price equates to a premium to the net asset value per share at the time of the transaction.

As a result of this issue, the total number of ordinary shares in issue now stands at 173,969,428 and the total number of voting rights in the Company is 173,969,428. There are no shares held in treasury.

The above figure of 173,969,428 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The Company confirms that application for admission will be made to London Stock Exchange plc and it is expected that admission will occur at 8:00 a.m. on 2 March 2020.

For further information, please contact:

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.